Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: | Clindamycin-hameln (300mg/2ml) |
Active Ingredient: | Clindamycin phosphate 178.23mg/mL equivalent to clindamycin 150mg/mL |
Dosage Form: | Solution for injection |
New Zealand Sponsor: | Max Health Limited |
Manufacturer: | Siegfried Hameln GmbH, Hameln, Germany |
Product: | Clindamycin-hameln (600mg/4ml) |
Active Ingredient: | Clindamycin phosphate 178.23mg/mL equivalent to clindamycin 150mg/mL |
Dosage Form: | Solution for injection |
New Zealand Sponsor: | Max Health Limited |
Manufacturer: | Siegfried Hameln GmbH, Hameln, Germany |
Product: | Codral Mucus Cough Forte Strength |
Active Ingredients: | Bromhexine hydrochloride 0.8mg/mL Guaifenesin 20mg/mL |
Dosage Form: | Oral solution |
New Zealand Sponsor: | Johnson & Johnson (New Zealand) Limited |
Manufacturer: | Shanghai Johnson & Johnson Pharmaceuticals Limited, Shanghai, China |
Dated this 22nd day of August 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).